| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1038/NCPCARDIO0602 |
| P698 | PubMed publication ID | 16810174 |
| P50 | author | Paul A Gurbel | Q89230591 |
| P2093 | author name string | Udaya S Tantry | |
| P2860 | cites work | Central role of the P2Y12 receptor in platelet activation | Q24618777 |
| Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance | Q28166663 | ||
| Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions | Q28167983 | ||
| Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome | Q28168804 | ||
| Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction | Q28168881 | ||
| Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting | Q28171392 | ||
| A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite | Q28174186 | ||
| Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study | Q28176594 | ||
| Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial | Q28181168 | ||
| Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel | Q28181620 | ||
| Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment | Q28185431 | ||
| Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug | Q28187017 | ||
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
| Resistance to antiplatelet drugs: current status and future research | Q28192298 | ||
| Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study | Q28193340 | ||
| Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial | Q28194232 | ||
| Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin | Q28195019 | ||
| Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial | Q28195423 | ||
| Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events | Q28195656 | ||
| Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity | Q28196405 | ||
| Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation | Q28196513 | ||
| Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial | Q28199508 | ||
| Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy | Q28209140 | ||
| Platelet activation in type 2 diabetes mellitus | Q28210554 | ||
| The difference between clopidogrel responsiveness and posttreatment platelet reactivity | Q28210845 | ||
| P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose | Q28211480 | ||
| Clopidogrel did not inhibit platelet function early after coronary bypass surgery: A prospective randomized trial | Q28212518 | ||
| Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy | Q28213372 | ||
| Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance | Q28213734 | ||
| Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets | Q28257658 | ||
| A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 | ||
| Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction | Q34168972 | ||
| Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. | Q34530924 | ||
| Platelet activation in myocardial ischemic syndromes | Q35821899 | ||
| Variability in platelet responsiveness to clopidogrel among 544 individuals. | Q40454244 | ||
| Individual variations of platelet inhibition after loading doses of clopidogrel | Q44148275 | ||
| Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies | Q44530596 | ||
| P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. | Q44684860 | ||
| Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization | Q44768151 | ||
| Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. | Q45121029 | ||
| Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. | Q45165021 | ||
| Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases | Q45213002 | ||
| Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study | Q45287859 | ||
| The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting | Q46464355 | ||
| Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers | Q46498134 | ||
| What is the best measure of thrombotic risks--pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation? | Q46738731 | ||
| Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes | Q46754050 | ||
| Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Ef | Q46783983 | ||
| Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study | Q46802481 | ||
| Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. | Q51095063 | ||
| Platelet, Not Endothelial, P-Selectin Is Required for Neointimal Formation After Vascular Injury | Q56944225 | ||
| ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article | Q56986819 | ||
| Pharmacokinetics of clopidogrel after administration of a high loading dose | Q80371510 | ||
| Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk | Q81873159 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | clopidogrel | Q410237 |
| P304 | page(s) | 387-95 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | Nature Clinical Practice Cardiovascular Medicine | Q15727036 |
| P1476 | title | Drug insight: Clopidogrel nonresponsiveness | |
| P478 | volume | 3 |
| Q36715768 | AZD6140. |
| Q37443855 | Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? |
| Q37914924 | Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents |
| Q38068595 | Antiplatelets in acute coronary syndrome: personal perspectives. |
| Q34019082 | Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy |
| Q35447163 | Cardiovascular pharmacogenomics |
| Q35823453 | Change of Platelet Reactivity to Antiplatelet Therapy after Stenting Procedure for Cerebral Artery Stenosis: VerifyNow Antiplatelet Assay before and after Stenting |
| Q27011524 | Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation |
| Q51906913 | Clopidogrel poor responders: an objective definition based on Bayesian classification. |
| Q38265442 | Comparison of new adenosine diphosphate receptor antagonists with clopidogrel in patients with coronary artery disease: a meta-analysis. |
| Q36865066 | Contemporary use of clopidogrel in patients with coronary artery disease |
| Q37781893 | Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery |
| Q37807398 | Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel |
| Q34352152 | Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease |
| Q37907918 | Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists |
| Q51905748 | Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. |
| Q33863833 | Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group |
| Q30450312 | High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study |
| Q37203987 | Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome |
| Q41343370 | Individualised dual antiplatelet therapy in a patient with short bowel syndrome after acute myocardial infarction with coronary artery stenting |
| Q37139179 | Influence of genetic variations on levels of inflammatory markers of healthy subjects at baseline and one week after clopidogrel therapy; results of a preliminary study |
| Q35635382 | Monitoring Residual Platelet Activity Among Patients With Acute Coronary Syndrome Post-PCI by Modified Impedance Whole Blood Platelet Aggregation and Release Method |
| Q38621049 | On-treatment platelet reactivity: State of the art and perspectives. |
| Q42185272 | Oral antiplatelet therapy in acute coronary syndromes: update 2012. |
| Q37562606 | P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. |
| Q37339517 | P2Y12 inhibitors in cardiovascular disease: focus on prasugrel |
| Q39221284 | P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation |
| Q37877165 | Personalized antiplatelet therapy: review of the latest clinical evidence |
| Q47554139 | Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine |
| Q38116753 | Pharmacogenomics of anti-platelet and anti-coagulation therapy |
| Q27022443 | Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? |
| Q34019342 | Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers |
| Q43187673 | Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects |
| Q38154211 | Pharmacology of antiplatelet agents |
| Q44479790 | Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target |
| Q37905028 | Prasugrel resistance: fact or fiction |
| Q98939322 | Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial |
| Q37540088 | Recent developments in clopidogrel pharmacology and their relation to clinical outcomes |
| Q44264585 | Resistance to high-maintenance dose of prasugrel treated by ticagrelor: a case report |
| Q40010554 | Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease |
| Q92075011 | Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing |
| Q36116104 | Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder |
| Q42000079 | Successful prasugrel rescue therapy in clopidogrel resistant patients who had recurrent stent thrombosis of drug-eluting-stent: the role of prasugrel in clopidogrel nonresponders |
| Q39249688 | The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics |
| Q33751281 | The impact of smoking on post-clopidogrel platelet reactivity in patients with acute myocardial infarction. |
| Q33776115 | The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting |
| Q84707921 | [Perioperative management of patients with coronary stents in non-cardiac surgery] |
Search more.